IRAK

Cat. No.

A33668

CAS No.

2760328-82-1

IRAK1/4/pan-FLT3 Kinase-IN-1

IRAK1/4/pan-FLT3 Kinase-IN-1 is a selective inhibitor targeting IRAK1, IRAK4, and FLT3 kinases, demonstrating IC50 values of 5 nM for IRAK1, 0.6 nM for IRAK4, and less than 0.5 nM for FLT3. This compound exhibits strong pharmacokinetic properties, indicating its potential for therapeutic application in acute myeloid leukemia research. Its efficacy in promoting survival suggests it may serve as a valuable tool for exploring novel treatment strategies in hematological malignancies.

Cat. No.

A33689

CAS No.

2923221-56-9

Lomonitinib

Lomonitinib is a potent and selective pan-FLT3/IRAK4 inhibitor that demonstrates significant antitumor activity. It is particularly relevant for research involving myeloid leukemia, where it may offer insights into therapeutic strategies targeting these pathways. Its unique mechanism of action makes it a valuable tool for investigating the roles of FLT3 and IRAK4 in cancer biology.

Cat. No.

A33728

CAS No.

2193085-94-6

NCGC1481

NCGC1481 is a potent inhibitor of FLT3, IRAK1, and IRAK4, displaying IC50 values of

Cat. No.

A34333

CAS No.

1103508-80-0

Tepotinib hydrochloride

Synonyms: EMD-1214063 hydrochloride

Tepotinib hydrochloride is a highly selective, reversible, ATP-competitive inhibitor of c-Met, exhibiting an IC50 of 3 nM and over 200-fold selectivity for c-Met compared to other kinases such as IRAK4, TrkA, Axl, IRAK1, and Mer. This compound effectively inhibits c-Met phosphorylation and promotes autophagy. Tepotinib hydrochloride demonstrates significant antitumor activity and is applicable in cancer research targeting c-Met-driven pathways.

Cat. No.

A35442

CAS No.

1610017-20-3

BMS-986126

BMS-986126 is a potent and selective inhibitor of IRAK4, with an IC50 value of 5.3 nM. It effectively disrupts MyD88-dependent signaling pathways, thereby attenuating inflammatory responses associated with autoimmune conditions. In preclinical studies, BMS-986126 has demonstrated significant efficacy in murine models of lupus, including MRL/lpr and NZB/NZW strains. This compound is valuable for research applications related to systemic lupus erythematosus (SLE) and other autoimmune diseases.

Cat. No.

A40790

CAS No.

2597345-07-6

UR241-2

UR241-2 is a selective inhibitor of IRAK4, targeting the IL-1–induced IRAK1/4 signaling pathway. It effectively suppresses NF-κB activation and the phosphorylation of p65 and p38, contributing to a reduction in leukemia stem cell clonogenicity. UR241-2 also serves as a valuable ligand for developing PROTAC degraders targeting IRAK4, making it a suitable tool for research in acute myeloid leukemia.

Cat. No.

A64901

CAS No.

1931994-81-8

Zabedosertib

Synonyms: BAY 1834845

Zabedosertib is a selective inhibitor of IRAK4, a protein kinase integral to the signaling pathways of innate immune responses triggered by Toll-like receptors. With an IC50 of 3.55 nM, Zabedosertib demonstrates significant immunomodulatory effects, specifically exhibiting anti-inflammatory activity against IL-1β, lipopolysaccharide (LPS), and Imiquimod-induced inflammation. This compound is suitable for research applications focused on exploring innate immunity and inflammation modulation.

Cat. No.

A64902

CAS No.

2227368-54-7

JH-X-119-01

JH-X-119-01 is a selective inhibitor of interleukin-1 receptor-associated kinases 1 (IRAK1) that demonstrates significant potential in immunological research. With an IC50 of 9 nM, JH-X-119-01 effectively inhibits IRAK1 activity without affecting IRAK4 at concentrations up to 10 μM. This compound has been shown to mitigate LPS-induced sepsis in animal models, making it a valuable tool for studies focused on inflammation and sepsis-related pathways.

Cat. No.

A64903

CAS No.

2408839-73-4

Edecesertib

Synonyms: GS-5718

Edecesertib is a selective and potent inhibitor of the interleukin-1 receptor-associated kinase 4 (IRAK-4). It exhibits significant anti-inflammatory activity, making it valuable in the study of inflammatory diseases. Edecesertib is applicable in research focused on rheumatoid arthritis (RA) and lupus erythematosus (LE), contributing to the understanding of therapeutic targets in these conditions.

Cat. No.

A64904

CAS No.

2591344-30-6

JH-X-119-01 hydrochloride

JH-X-119-01 hydrochloride is a selective inhibitor of interleukin-1 receptor-associated kinase 1 (IRAK1), a key player in inflammatory signaling pathways. This compound demonstrates significant potential in reducing LPS-induced sepsis in murine models, indicating its utility in studying inflammatory disorders. Researchers can leverage JH-X-119-01 hydrochloride to explore IRAK1's role in immune responses and develop targeted therapies for sepsis and related conditions.

Cat. No.

A64905

CAS No.

2170694-04-7

IRAK4-IN-21

IRAK4-IN-21 is a potent and selective inhibitor of IRAK4, exhibiting IC50 values of 5 nM for IRAK4 and 56 nM for TAK1. This orally active compound effectively inhibits interleukin-23 (IL-23) production with an IC50 of 0.17 μM. IRAK4-IN-21 is valuable for research applications in autoimmune diseases, particularly in the context of plaque psoriasis and psoriatic arthritis.

Cat. No.

A64906

CAS No.

2454244-02-9

IRAK4-IN-6

IRAK4-IN-6 is a selective inhibitor of IRAK4, demonstrating an IC50 of 4 nM. It effectively targets the MyD88 L265P mutant variant associated with diffuse large B cell lymphoma, making it a valuable tool for research in oncology and immune signaling pathways. Its oral efficacy supports in vivo studies, facilitating investigations into IRAK4's role in tumorigenesis and potential therapeutic interventions.

Cat. No.

A64907

CAS No.

2170694-05-8

IRAK4-IN-22

IRAK4-IN-22 is a selective IRAK4 inhibitor with potent activity, exhibiting IC50 values of 3 nM for IRAK4 and 17 nM for TAK1. This compound effectively inhibits IL-23 production with an IC50 of 0.10 µM, making it a valuable tool for research into autoimmune conditions such as plaque psoriasis and psoriatic arthritis. Its oral bioavailability enhances its suitability for in vivo studies, facilitating investigations into the therapeutic potential of targeting IRAK4 in inflammatory diseases.

Cat. No.

A64909

CAS No.

2573211-25-1

BIO-7488

BIO-7488 is a selective IRAK4 inhibitor with a potent IC50 of 0.5 nM, designed to cross the blood-brain barrier effectively. This compound inhibits the production of pro-inflammatory cytokines, including IL-1β, TNFα, and IL-6, displaying significant anti-inflammatory properties in both LPS-induced and distal hypoxic-middle cerebral artery occlusion ischemic stroke models. BIO-7488 is a valuable reagent for researching neuroinflammatory disorders, particularly in the context of ischemic stroke.

Cat. No.

A64910

CAS No.

1931994-80-7

IRAK4-IN-20

IRAK4-IN-20 is a potent inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), showcasing an IC50 of 3.55 nM. This compound is indicated for research into inflammatory conditions, particularly acute respiratory distress syndrome (ARDS). Its mechanism of action makes it a valuable tool for studying IRAK4's role in immune signaling pathways and related therapeutic interventions.

Cat. No.

A64911

CAS No.

2095615-97-5

GLPG2534

GLPG2534 is a selective inhibitor of IRAK4, exhibiting IC50 values of 6.4 nM and 3.5 nM for human and mouse IRAK4 respectively. This compound effectively modulates inflammatory signaling pathways involved in immune responses. GLPG2534 is suitable for research aimed at understanding and developing treatments for inflammatory skin diseases.

Cat. No.

A64914

CAS No.

2667681-71-0

IRAK4-IN-14

IRAK4-IN-14 is a potent, selective inhibitor of IRAK4, demonstrating an IC50 of 0.003 µM. This orally active compound exhibits favorable pharmacokinetic properties in both rat and mouse models. IRAK4-IN-14 has shown synergy in vitro against MyD88/CD79 double mutant ABC-DLBCL when used in combination with Acalabrutinib, making it a valuable tool for research in oncology and inflammation pathways.

Cat. No.

A64915

CAS No.

1817628-40-2

PF-06426779

PF-06426779 is a potent and selective inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4), displaying an IC50 of 0.3 nM. This compound effectively modulates inflammatory signaling pathways and is useful in the study of diseases related to dysregulated immune responses. Researchers can leverage PF-06426779 in experimental settings exploring the roles of IRAK4 in cellular processes and potential therapeutic interventions in inflammation-driven disorders.

Cat. No.

A64916

CAS No.

301675-24-1

IRAK-4 protein kinase inhibitor 2

IRAK-4 protein kinase inhibitor 2 selectively targets interleukin-1 receptor-associated kinase-4 (IRAK-4) with an IC50 of 4 μM. This inhibitor is instrumental in studying inflammatory and immune-related diseases, offering valuable insights into the mechanisms underlying these conditions. Its effective application in research may lead to better understanding and potential therapeutic developments in immune responses.

Cat. No.

A64917

CAS No.

2410393-15-4

HS271

HS271 is a selective inhibitor of IRAK4, demonstrating potent activity with an IC50 of 7.2 μM. This compound exhibits superior enzymatic and cellular efficacy, making it suitable for studies investigating IRAK4-mediated signaling pathways. HS271’s excellent pharmacokinetic properties further enhance its utility in various biological research applications focused on inflammatory processes and immune response modulation.

Cat. No.

A64918

CAS No.

2102170-43-2

GNE-2256

GNE-2256 is a potent inhibitor of IRAK4 (Interleukin 1 receptor associated kinase 4) with a Ki of 1.4 nM, demonstrating high selectivity for this target. It effectively reduces IL-6 production with an IC50 of 190 nM, making it a valuable tool for investigating inflammatory responses and signaling pathways. GNE-2256 is suitable for studies involving autoimmune diseases and other conditions related to aberrant IL-6 signaling.

Cat. No.

A64919

CAS No.

2070014-89-8

IRAK inhibitor 4 (trans)

IRAK inhibitor 4 (trans) is a selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4). This compound has demonstrated significant efficacy in blocking IRAK4 activation, thereby modulating the downstream signaling pathways involved in inflammatory responses. It is widely used in research applications focusing on inflammatory disorders and signaling pathways associated with innate immunity.

Cat. No.

A64920

CAS No.

2033070-97-0

IRAK4-IN-8

IRAK4-IN-8 is a potent inhibitor of IRAK4, an essential kinase in the interleukin-1 receptor (IL-1R) and Toll-like receptor (TLR) signaling pathways. By selectively inhibiting IRAK4, it modulates downstream inflammatory responses, making it a valuable tool for studying immune pathways. Its primary applications include research on autoimmune disorders, cancer immunotherapy, and the development of novel anti-inflammatory drugs.

Cat. No.

A64921

CAS No.

3032075-26-3

IRAK4-IN-18

IRAK4-IN-18 is a selective inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), exhibiting an IC50 value of 15 nM. This compound is effective in inhibiting lipopolysaccharide (LPS)-induced interleukin-23 (IL-23) production in THP-1 and dendritic cells, demonstrating its potential to modulate inflammatory responses. IRAK4-IN-18 is applicable for research into arthritis and related inflammatory diseases.

Cat. No.

A64922

CAS No.

2760329-44-8

IRAK1/4/pan-FLT3 Kinase-IN-2

IRAK1/4/pan-FLT3 Kinase-IN-2 is a dual inhibitor targeting IRAK1, IRAK4, and FLT3 with IC50 values of 10 nM, 0.7 nM, and